entertainment -WSS

entertainment

author：Wikipedia 2025-09-30 18:17:29 - browse：3354

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

A group of advisers to the Food and Drug Administration voted in favor of Alnylam Pharmaceuticals’ treatment for a debilitating heart disease Wednesday, but only after a day-long debate challenging whether the drug’s modest observed effects were actually meaningful for patients.

The group of independent experts voted 9-3 that the benefits of Alnylam’s drug, called patisiran, outweighed its risks for patients with ATTR-CM, a progressive disease that leads to fatal heart failure if left untreated. The FDA, which is not required to follow the advice of advisers, is expected to make a final decision on patisiran by Oct. 8.

“It’s like a light wind blowing in favor of patisiran over placebo,” said David Cella, a neurologist at the Northwestern University Feinberg School of Medicine who voted in favor of patisiran. David Moliterno, a cardiologist at the University of Kentucky, added that “the good news in this story is that while there may be a small benefit, it doesn’t look like there’s a signal for harm.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Boston's new lab space is opening empty

WSS

Sea level rise could wash away turtle breeding grounds around the world, researchers say

The thinking behind the controversial eating disorder chatbot Tessa

Novo: Oral version of Ozempic leads to 15% weight loss

President Biden's budget: Here's what you might have missed

Why scientists need input from humanists on sensitive research

Reanimated hearts work just as well for transplants, study finds

hotspot

entertainment

entertainment

Wildfire smoke exposes gaps in outdoor worker protections

The thinking behind the controversial eating disorder chatbot Tessa

The high cost of giving birth even with insurance

Boston's new lab space is opening empty

New air purifier tech could be key to improving indoor air quality

Reanimated hearts work just as well for transplants, study finds

The cancer drug shortage isn’t new — and neither are the solutions

EPA limits use of carcinogenic gas for sterilizing medical devices

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

FDA advisers back CAR

knowledge

President Biden's budget: Here's what you might have missed

Boston's new lab space is opening empty

Steward Health Care Massachusetts hospitals face fiscal disaster

Readout Newsletter: CAR

Steward Health Care Massachusetts hospitals face fiscal disaster

Can medical device makers keep up in the race to treat obesity?

focus

hotspot

knowledge

hotspot